Mark Rothera - 30 Nov 2023 Form 4 Insider Report for Viracta Therapeutics, Inc. (VIRX)

Role
President and CEO, Director
Signature
Daniel Chevallard, as Attorney-in-Fact
Issuer symbol
VIRX
Transactions as of
30 Nov 2023
Transactions value $
$49,362
Form type
4
Filing time
04 Dec 2023, 16:54:41 UTC
Previous filing
17 Mar 2023
Next filing
13 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIRX Common Stock Purchase $25,734 +52,094 $0.494 52,094 30 Nov 2023 Direct F1
transaction VIRX Common Stock Purchase $23,627 +47,906 +91.96% $0.4932 100,000 01 Dec 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the weighted average share price of an aggregate total of 52,094 shares purchased in the price range of $0.48 to $0.51 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F2 Represents the weighted average share price of an aggregate total of 47,906 shares purchased in the price range of $0.4750 to $0.5130 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.